Validation of Bioelectrical Impedance Analysis for the Measurement of Appendicular Lean Mass in Older Women

Kayla Mahoney
University of Rhode Island, krounds@my.uri.edu

Follow this and additional works at: https://digitalcommons.uri.edu/theses

Recommended Citation
https://digitalcommons.uri.edu/theses/845

This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
VALIDATION OF BIOELECTRICAL IMPEDANCE ANALYSIS FOR THE
MEASUREMENT OF APPENDICULAR LEAN MASS IN OLDER WOMEN

BY

KAYLA MAHONEY

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
IN
KINESIOLOGY

UNIVERSITY OF RHODE ISLAND

2016
ABSTRACT

Segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) has been shown to be a valid, more portable, and less expensive alternative to dual energy x-ray absorptiometry (DXA) for the measurement of appendicular lean mass (ALM) in several populations. However, few studies have examined the validity of SMF-BIA specifically among populations of older women classified as sarcopenic or dynapenic. The aim of this cross sectional study was to investigate the accuracy of SMF-BIA compared to the gold standard DXA for the measurement of ALM among sarcopenic and/or dynapenic older women. Physical function, ALM, strength, and anthropometric tests were performed to determine the presence of sarcopenia and/or dynapenia in a sample of 25 older (72.3 ± 4.6 years) women using established sarcopenia classification criteria. Estimation of ALM using SMF-BIA and DXA were performed under standardized testing conditions. Both techniques were administered within the same hour with participants adequately hydrated, fasted, following urine elimination, and while wearing hospital scrubs. A Pearson correlation coefficient was used to determine a relationship between the two methods for ALM and agreement between the two techniques was assessed using a Bland-Altman plot method. Statistical significance was set at p < 0.05. A significant and strong correlation was observed between the two techniques with a Pearson’s correlation coefficient of 0.88 (95% CI = 0.75 to 0.95; p < 0.001). The Bland-Altman plot showed a mean difference of 0.5 kg and an indication of overall agreement between techniques. However, SMF-BIA overestimated ALM for one participant (-2.9 kg, 95% CI = -3.76 to -2.03) and underestimated ALM for another participant (1.8 kg, 95% CI = 0.98 to 2.71) compared
to DXA. The findings indicate overall agreement between SMF-BIA and DXA for the estimation of ALM among older women with characteristics of sarcopenia, but SMF-BIA may overestimate or underestimate ALM in some individuals. These data suggest that SMF-BIA may be an acceptable alternative to DXA for the assessment of ALM in older women with characteristics of sarcopenia.
ACKNOWLEDGEMENTS

The funding for the URI Resistance Exercise Study to Reclaim Lean Mass and Strength (URI RESTORE ME) was generously provided by the College of Human Science and Services. The study was conducted by the Department of Kinesiology and the Department of Nutrition and Food Sciences. I would first like to extend sincere thanks to all faculty involved with the project including Dr. Delmonico, Dr. Xu, Dr. Hatfield, and Dr. Lofgren. I am thankful to have been offered support and guidance by each of the investigators along the way. I would like to recognize Dr. Delmonico’s efforts in particular as my primary advisor for the project. If it were not for his valuable feedback, organization, motivation, and passion for advancing the field of kinesiology, completing a thesis project would not have been possible. I would also like to thank my fellow graduate study coordinators, Sam Slezak and Emily Renna for all of their hard work and dedication through all phases of the study. Finally, I would like to thank my husband Brian for supporting me over the past two years while I struggled to balance school, three jobs, and a social life. The support from all of the above mentioned individuals has ultimately led to successful completion of my thesis in addition to the advancement of knowledge in the field of sarcopenia and body composition research.
PREFACE

This thesis is written to comply with the University of Rhode Island graduate school manuscript format. The thesis document contains one manuscript: *Validation of Bioelectrical Impedance Analysis for the Measurement of Appendicular Lean Mass in Older Women*. The manuscript has been written in a form formatted for publication in the *International Journal of Body Composition Research*. 
TABLE OF CONTENTS

ABSTRACT ........................................................................................................... ii

ACKNOWLEDGEMENTS .................................................................................... iv

PREFACE ........................................................................................................ v

TABLE OF CONTENTS ....................................................................................... vi

LIST OF TABLES ................................................................................................ viii

LIST OF FIGURES ............................................................................................. ix

MANUSCRIPT: Validation of Bioelectrical Impedance Analysis for the Measurement
of Appendicular Lean Mass in Older Women ......................................................... 1

   ABSTRACT ....................................................................................................... 2

   INTRODUCTION .............................................................................................. 4

   METHODOLOGY .............................................................................................. 6

   RESULTS .......................................................................................................... 12

   DISCUSSION .................................................................................................. 14

   CONCLUSION ................................................................................................. 18

   REFERENCES ................................................................................................. 19

   TABLES ........................................................................................................... 22

   FIGURES ......................................................................................................... 25
APPENDICES

APPENDIX A: Review of the Literature.................................28

APPENDIX B: Phone Screening Assessment.............................46

APPENDIX C: Consent form for Research.................................51

APPENDIX D: Medical History Form.....................................57

APPENDIX E: Baseline Data Collection Sheet............................63

APPENDIX F: Yale Physical Activity Survey (YPAS).....................69

APPENDIX G: Dietary Screening Tool (DST)...............................73
LIST OF TABLES

**Table 1.** Baseline Participant Characteristics

**Table 2.** Fisher’s Exact Test for Sarcopenia Classification Based on European Working Group on Sarcopenia in Older People (EWGSOP) Criteria Comparing Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy X-ray Absorptiometry (DXA)

**Table 3.** Fisher’s Exact Test for Sarcopenia Classification Based on the Foundation for the National Institute of Health Sarcopenia Project (FNIHSP) Definition Comparing Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy X-ray Absorptiometry (DXA)
LIST OF FIGURES

Figure 1. Study Flow Chart

Figure 2. Pearson’s Correlation Coefficient between Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy X-ray Absorptiometry (DXA) for the Measurement of Appendicular Lean Mass (ALM)

Figure 3. Bland-Altman Plot Comparing Appendicular Lean Mass (ALM) by Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and DualEnergy X-ray Absorptiometry (DXA)
Validation of Bioelectrical Impedance Analysis for the Measurement of Appendicular Lean Mass in Older Women

This manuscript was prepared for submission to: The International Journal of Body Composition Research

Manuscript Type: Original Research

Authors: Kayla B. Mahoney\textsuperscript{a}, Sam G. Slezak\textsuperscript{a}, Emily N. Renna\textsuperscript{a}, Furong Xu\textsuperscript{a}, Ingrid E. Lofgren\textsuperscript{b}, Disa L. Hatfield, Matthew J. Delmonico\textsuperscript{a}

\textsuperscript{a} Department of Kinesiology, University of Rhode Island, Independence Square II, Kingston, Rhode Island, 02881, USA

\textsuperscript{b} Department of Nutrition and Food Sciences, University of Rhode Island, Ranger Hall, Kingston, Rhode Island, 02881, USA

Funding support: Funding provided by the College of Human Science and Services at the University of Rhode Island

Conflict of interest: We certify that no party having direct interest in the results of the research that support this article.

Acknowledgements: The authors would like to extend their gratitude to undergraduate research assistants from the Department of Kinesiology, and to all of the participants for their commitment and involvement in the study.
ABSTRACT

Objective: Segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) has been shown to be a valid, more portable, and less expensive alternative to dual energy x-ray absorptiometry (DXA) for the measurement of appendicular lean mass (ALM) in several populations. However, few studies have examined the validity of SMF-BIA specifically among populations of older women classified as sarcopenic or dynapenic. The aim of this cross sectional study was to investigate the accuracy of SMF-BIA compared to the gold standard DXA for the measurement of ALM among sarcopenic and/or dynapenic older women.

Methods: Physical function, ALM, strength, and anthropometric tests were performed to determine the presence of sarcopenia and/or dynapenia in a sample of 25 older (72.3 ± 4.6 years) women using established sarcopenia classification criteria. Estimation of ALM using SMF-BIA and DXA were performed under standardized testing conditions. Both techniques were administered within the same hour with participants adequately hydrated, fasted, following urine elimination, and while wearing hospital scrubs. A Pearson correlation coefficient was used to determine a relationship between the two methods for ALM and agreement between the two techniques was assessed using a Bland-Altman plot method. Statistical significance was set at p < 0.05.

Results: A significant and strong correlation was observed between the two techniques with a Pearson’s correlation coefficient of 0.88 (95% CI= 0.75 to 0.95; p < 0.001). The Bland-Altman plot showed a mean difference of 0.5 kg and an indication of overall agreement between techniques. However, SMF-BIA overestimated ALM
for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and underestimated ALM for another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared to DXA.

Discussion: The findings indicate overall agreement between SMF-BIA and DXA for the estimation of ALM among older women with characteristics of sarcopenia, but SMF-BIA may overestimate or underestimate ALM in some individuals. These data suggest that SMF-BIA may be an acceptable alternative to DXA for the assessment of ALM in older women with characteristics of sarcopenia.

Keywords: Sarcopenia, DXA
INTRODUCTION

Sarcopenia is defined as the progressive loss of muscle mass, physical function, and strength (i.e. dynapenia) which accelerates with aging [1–3]. Sarcopenia is associated with several adverse health outcomes among older adults including frailty, weakness, functional decline, increased risk of falls and fractures, and loss of independence [1,2]. In the year 2000, estimated healthcare costs associated with sarcopenia were $12.6 billion for older men, and $29.5 billion for older women [4]. The economic burden associated with sarcopenia is likely far higher today particularly in women, as they have a greater life expectancy and risk for functional impairment compared to men [5]. Although a universally accepted definition for sarcopenia is currently lacking, several working groups have convened to establish operational criteria for classification including measures of physical function, strength, and muscle mass.

While a wide range of techniques are available for assessing muscle mass, dual energy X-ray absorptiometry (DXA) is considered as the gold standard in research and clinical practice to determine appendicular lean mass (ALM) despite its limitations including exposure to radiation, expense, and lack of portability [2,6–8]. Thus, it is critical to find alternative methods for ALM assessment.

The use of segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) for the measurement of muscle mass has been accepted as a valid, more portable, and less expensive alternative in several populations [9–12] including older women [13,14]. While one study has validated the use of SMF-BIA for the estimation of ALM among a general population of older women [13], the device has not yet been
validated for the assessment of ALM and its application to sarcopenia identification based on several accepted definitions. Thus, the purpose of this investigation was to assess whether SMF-BIA would accurately quantify ALM compared to DXA among a population of older women with characteristics of sarcopenia and/or dynapenia. It was hypothesized that SMF-BIA would be in agreement with DXA for the estimation of ALM. A secondary aim was to examine if SMF-BIA similarly classifies older women as sarcopenic compared to DXA based on ALM compared to height or body mass index (BMI) using established cut-points.
METHODS

Study Design

The study utilized a cross-sectional design to compare differences between SMF-BIA and DXA for the estimation of ALM among 25 older women pre-screened for the presence of sarcopenia and/or dynapenia (reduced strength). The participants were pre-screened for entry into a 12-week University of Rhode Island Institutional Review Board approved, Resistance Exercise Study to Reclaim Lean Muscle and Strength (URI RESTORE ME Project: IRB # HU1415-168). The two techniques being compared for this study were performed at baseline of the URI RESTORE ME project.

Participants

Community dwelling women (n = 25) aged 65 to 84 years were recruited from Rhode Island via flyers, newspaper ads, press releases, and by word of mouth within local senior centers. All women initially eligible based on information provided during a telephone screening were invited to an onsite orientation and pre-screening assessment. During pre-screening, all women provided written informed consent and were evaluated for the presence of sarcopenia and/or dynapenia determined from the assessment of lean mass, height, weight, grip strength, single chair stand, and gait speed based on the European Working Group on Sarcopenia in Older People (EWGSOP) and the Foundation for the National Institute of Health Sarcopenia Project (FNIHSP) criteria. The pre-screening visit determined that 38 participants were eligible based on the sarcopenia criteria. Although eligible, 13 participants were
subsequently eliminated from the final cohort due to questions of time commitment or orthopedic concerns that would limit full participation in the intervention phase of the project. Figure 1 summarizes each phase of study recruitment.

**Outcome Measures**

All testing sessions were standardized with participants arriving in the morning in a fasted state. Participants were instructed to arrive well hydrated and having not exercised. Both techniques for measuring body composition were performed on the same day, within the same hour, and following urine elimination. All participants were dressed in hospital scrubs for both methods.

*Appendicular Lean Mass:* ALM was estimated using fan-beam technology (GE Lunar iDXA, Waukesha, WI). The DXA scans were performed using a standardized procedure for patient positioning by a licensed radiology technician. The DXA scans provided estimations of ALM defined as the total skeletal muscle mass from the right arm, left arm, right leg, and left leg measured in kilograms.

In addition to DXA, a SMF-BIA was used to estimate segmental muscle mass whereby ALM could then be calculated. The InBody 570 Biospace device (Biospace Co, Ltd, Korea) was used according to the manufacturer’s guidelines during both the pre-screening assessment (to determine sarcopenia status) and baseline testing to assess ALM. Body composition is estimated via SMF-BIA using the difference of conductivity of various tissues due to the differences in their biological characteristics. The risk of adverse events is low using SMF-BIA and its use has been performed safely on older adults in other studies [15]. As a precaution, women with a cardiac pacemaker or internal defibrillator were not tested.
Sarcopenia Status: Prior to the collection of baseline testing data, participants completed pre-screening to determine their eligibility as presenting with sarcopenia and/or dynapenia. An algorithm for determining eligibility was developed based on a combination of both the EWGSOP and FNIHSP working definitions for sarcopenia. Initial ALM estimates using SMF-BIA in addition to outcomes of physical function using the gait speed, single chair stand, and grip strength tests were included in the algorithm. The cut-points established for each criteria included an ALM < 5.67 kg/m$^2$ or ALM/BMI < 0.512, a grip strength < 20 kg or inability to complete a single chair stand, and a gait speed < 0.8 m/s [2,16]. Women selected were classified as having low lean mass (LM), low strength, low function (slow gait), or all three characteristics.

Physical Function: As part of the short physical performance battery (SPPB) of tests, usual gait speed was measured during pre-screening and during baseline to assess physical function and as a fundamental criterion for defining sarcopenia status. Gait speed has been suggested as being included in routine evaluations as the sixth vital sign [7] as it is a strong predictor of major health outcomes and survival in older adults [6]. The EWGSOP, International Working Group (IWG), and FNIHSP are all in agreement that a gait speed < 0.8 m/s should be used as a cut-point for identifying sarcopenia in older adults [2,16,18]. Standardized protocols were utilized for administration of the gait speed test which required participants to walk 4 meters at a usual pace [19]. The test was repeated twice with the faster of the two trials recorded in seconds.

Muscle Strength: Grip strength is reliable, valid, and simple to administer in both clinical and community settings and is a predictor of mobility impairment
Grip strength was tested during pre-screening and during baseline using a handgrip dynamometer (Jaymar Hydraulic Dynamometer, J.A. Preston, Corp., Jackson, MS). The test was performed with the participant seated in a chair with the elbow bent to 90 degrees using a standardized protocol [22]. The dynamometer was set accordingly based on each individual’s hand size so that the second knuckle of all four fingers rested flat on the handle. Two trials were performed on each hand and the highest score was recorded in kilograms without accounting for hand dominance. Grip strength values < 20 kg were also used as criteria for determining the presence of sarcopenia and/or dynapenia. Participants also completed a single chair stand test to assess lower body strength using a standardized protocol [23]. The test required that the participant rise from a chair with the arms crossed over the chest and with both feet flat on the floor. The ability or inability to rise from the chair was recorded and used to classify individuals as weak (i.e. dynapenia).

**Anthropometrics:** Each participant’s height and weight were measured twice and the average of the two readings were used. Height and weight were measured with each participant barefoot and wearing hospital scrubs. Height was measured using a wall mounted stadiometer and weight was recorded using the InBody 570 SMF-BIA device. From these measurements, BMI was calculated by dividing the participants weight in kilograms by their height in meters squared.

**Other Measures**

**Physical Activity:** To assess each participant’s physical activity level, the Yale Physical Activity Survey (YPAS) was administered during baseline testing. The YPAS quantifies the type and intensity of physical activity among older adults
estimating total energy expenditure (kcals/week) and a total activity summary index. The YPAS has been shown to be a valid measurement for the assessment of physical activity among older adults [24]. The YPAS was used to describe physical activity patterns of the participant population.

**Dietary Intake:** Participants completed a Dietary Screening Tool (DST) developed for older adults at baseline to assess dietary patterns [25]. The DST identifies 3 levels of nutritional risk: at risk (< 60), at possible risk (60 to 75), and not at risk (> 75) [26]. Nutritional risk assessed with the DST was used to describe the participant population.

**Statistical Analysis**

Estimated between-group differences were calculated for the primary outcomes, and a paired t-test was used to compare differences in estimated ALM by SMF-BIA and DXA. A previous study comparing SMF-BIA and DXA among frail women 75 years or older demonstrated an overall mean difference for ALM between the two techniques as 0.08 ± 0.05 kg [13]. Based on the findings of this study, a sample size of 16 were required to provide sufficient power (0.80) and alpha at 0.05.

Clinical and demographic characteristics of the participants are expressed as mean ± standard deviation. A Shapiro-Wilk test was performed to verify that data for the primary outcome variables were within normal distribution. To determine the strength of the relationship between the two variables, a Pearson moment correlation coefficient was performed. To test the primary hypothesis, a Bland-Altman method was employed to compare agreement between DXA and SMF-BIA whereby the
differences in techniques are plotted against the averages of the two techniques [27].

To test the secondary hypothesis, a Fisher’s exact test was used to compare sarcopenia status based on ALM between the two techniques. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS

A total of 25 female participants with a mean age of 72.3 ± 4.6 years were enrolled in this study. Demographic characteristics, anthropometric measures, indicators of physical functioning, physical activity, and dietary habits of the study population are summarized in Table 1.

A significant difference (p = 0.0145) was observed between DXA and SMF-BIA for the measurement of ALM by a mean of 0.5 kg for each participant. Additionally, a 4.3% error of ALM by SMF-BIA was observed compared to DXA as the gold standard (p = 0.0162). A significant and strong positive correlation was observed between SMF-BIA and DXA as indicated by a Pearson’s correlation coefficient of 0.88 (95% CI= 0.75 to 0.95, p < 0.001) highlighted in Figure 2. In addition, agreement between the two methods was assessed using a Bland-Altman plot (Figure 3). A mean difference of 0.5 kg (95% CI= -1.02 to -0.02) indicates overall agreement between SMF-BIA and DXA. However, SMF-BIA overestimated ALM for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and underestimated ALM for another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared to DXA.

When comparing sarcopenia status based on ALM measured by SMF-BIA and DXA, the Fisher’s exact test indicates a significant difference (p < 0.001) between the two techniques when using both the EWGSOP and FNIHSP criteria. Of the 25 women found to demonstrate characteristics of sarcopenia and/or dynapenia based on EWGSOP criteria during pre-screening, SMF-BIA identified less participants (n = 7) as sarcopenic compared to DXA (n = 11). While SMF-BIA and DXA similarly identified the normal and pre-sarcopenic participants, DXA was able to identify more
participants as having sarcopenia based on current EWGSOP criteria (Table 2).

Similarly, DXA was able to identify more participants as having low lean mass (n = 9) compared to SMF-BIA (n = 6) based on FNIHSP criteria (Table 3).
DISCUSSION

The results of this study indicate overall agreement between SMF-BIA and DXA for the estimation of ALM among older women with characteristics of sarcopenia and/or dynapenia. A significant and strong correlation ($r = 0.88$) and the lack of significant difference between the two techniques indicates acceptability of SMF-BIA compared to DXA. The Bland Altman plot provided a visual judgement of agreement between techniques with a mean overestimation of ALM by SMF-BIA of 0.5 kg. While most participants fell within the 95% limits of agreement, two outliers were identified. The plot indicates that SMF-BIA overestimated ALM but was not statistically different from DXA. The results of the present study are in line with previous studies which support that SMF-BIA is a valid, more portable, and affordable alternative to DXA for the estimation of ALM [7,9,10,13,14].

While the study indicates that SMF-BIA is a valid alternative to DXA, DXA appears to be more reliable for assessing ALM for diagnosing sarcopenia. Criteria for sarcopenia classification required that the participants ALM be $< 5.67$ kg/m² or ALM/BMI $< 0.512$ in combination with weak grip strength ($< 20$ kg) and/or slow gait speed ($< 0.8$ m/s). These findings suggest that SMF-BIA may overestimate ALM just enough to allow some participants to be above the sarcopenia ALM cut-off value. While the grip strength and gait speed functional outcomes stand alone to identify individuals at risk for sarcopenia, DXA is the most reliable method for identifying sarcopenic females based on ALM. Although overall agreement between SMF-BIA and DXA for the estimation of ALM was observed in this study, investigators should use caution when using some impedance models for diagnosing sarcopenia.
In agreement with these findings, previous studies have demonstrated that SMF-BIA is a valid alternative to DXA for the estimation of ALM among healthy adult [9,10] and older female participants [13,14]. Andersen et al. [10] determined that similar SMF-BIA devices, namely the InBody 520 and 720, were valid for the estimation of ALM among healthy young women between the ages of 18 and 49 years. While both devices were strongly correlated to DXA, \((r = 0.62 - 0.87)\) the conclusions were that SMF-BIA underestimated ALM by approximately 1.0 kg in the 25 female participants. Similar results were observed by Leahy et al. [9] with BIA underestimating arm and leg fat free mass by 0.2 kg (2.4 %) and 0.8 kg (3.4 %), respectively, in men and 0.2 kg (4.5 %) and 0.7 kg (4.4 %), respectively, in women \((p < 0.001)\). Another similar study identified SMF-BIA as an appropriate alternative to DXA for the estimation of fat mass, percent body fat, and total lean mass, but not for the evaluation of ALM among a healthy adult population between 18 and 85 years [12]. Although the present study identifies the InBody 570 SMF-BIA device to be a valid alternative to DXA, the tendency for SMF-BIA to overestimate or underestimate ALM in some participants did occur as consistent with previous study findings.

Conflicting results regarding the agreement between SMF-BIA and DXA specifically for the measurement of ALM among elderly women have also been reported in other similar studies [7,13,14]. Buckinx et al. [7] observed low agreement between the two methods among approximately 25 women in the subcategory of participants over the age of 65 \((n = 48)\) using a Bland-Altman plot method. The study reported a tendency for SMF-BIA to overestimate ALM by approximately 1.75 kg [7]. Other studies investigating older women report acceptable accuracy of SMF-BIA
compared to DXA for the estimation of ALM. Among an older female Japanese population (n = 330) aged 65 to 87 years old, SMF-BIA tended to underestimate ALM by 1.59 kg (95% CI= 1.49 to 1.68) [14]. Segmental multi-frequency BIA also provided acceptable accuracy for the estimation of ALM among frail women 75 years and older with a tendency to underestimate ALM (r = -1.42, p < 0.01) [13]. In the present study, despite significant differences in sarcopenia definitions between SMF-BIA and DXA, the Bland-Altman plot indicated overall agreement between the two methods for the estimation of ALM with a mean difference of 0.5 kg among the older female participants.

This study has both strengths and weaknesses. The main strength was the use of standardized testing conditions. All participants were instructed to arrive for testing fasted, well hydrated, having not exercised, and following urine elimination. These confounding variables were well-controlled in addition to SMF-BIA and DXA being performed within the same hour. Hydration status upon arrival for testing was assessed based on self-report in addition to a normal ratio of extracellular water to total body water content (ECW/TBW) estimated by SMF-BIA. All participants ECW/TBW ratios were within the normal range of 0.36 to 0.39 as defined by the InBody manufacturer. The use of DXA as the gold standard method for body composition analysis by which SMF-BIA could be compared was an additional strength of the present study.

Potential limitations include the small sample size and homogeneity of the participant population as the results may not be generalizable to other populations. A larger sample size of older women including those from different racial, ethnic, and
socioeconomic backgrounds could have demonstrated more similarity between SMF-BIA and DXA using Fisher’s exact analysis. The present study was limited to investigating the validity of only one of many SMF-BIA devices, the InBody 570. Additionally, the study was cross sectional therefore, future studies should examine changes in ALM longitudinally and following interventions.
CONCLUSION

While previous studies have investigated the validity of SMF-BIA for estimation of ALM compared to DXA among older women, this is the first study to validate SMF-BIA in a population of older women who present with sarcopenia and/or dynapenia. In conclusion, the present study confirmed overall agreement between SMF-BIA and DXA for the measurement of ALM among older women who present with characteristics of sarcopenia and/or dynapenia based on current definitions. It is possible however, that SMF-BIA may overestimate or underestimate ALM in some participants. While SMF-BIA is an acceptable, less expensive, and more portable alternative to DXA for measuring ALM, future studies are required using other devices and larger samples to justify that SMF-BIA is more realistic for clinical and epidemiological identification of sarcopenia based on current definitions.
REFERENCES


23. Roberts HC, Denison HJ, Martin HJ et al. A review of the measurement of grip strength in clinical and epidemiological studies: Towards a standardised


## TABLES

**Table 1. Baseline Participant Characteristics**

<table>
<thead>
<tr>
<th></th>
<th>Mean (SD)</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>72.3 (4.6)</td>
<td>66</td>
<td>81</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>65.3 (13.5)</td>
<td>47</td>
<td>100.7</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>159.8 (5.2)</td>
<td>149.9</td>
<td>168.9</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>25.7 (5.8)</td>
<td>18.9</td>
<td>42</td>
</tr>
<tr>
<td>% Body Fat</td>
<td>42.5 (6.3)</td>
<td>28.1</td>
<td>55.8</td>
</tr>
<tr>
<td>Gait Speed (meters/second)</td>
<td>0.97 (0.12)</td>
<td>0.68</td>
<td>1.18</td>
</tr>
<tr>
<td>Grip Strength (kg)</td>
<td>16.6 (3.7)</td>
<td>10</td>
<td>28</td>
</tr>
<tr>
<td>Physical Activity (kcals/week)</td>
<td>6,912 (3,270)</td>
<td>1,183</td>
<td>13,350</td>
</tr>
<tr>
<td>Physical Activity Index</td>
<td>49.6 (22.1)</td>
<td>16</td>
<td>103</td>
</tr>
<tr>
<td>Dietary Patterns</td>
<td>73.3 (6.4)</td>
<td>52</td>
<td>82</td>
</tr>
</tbody>
</table>

*Abbreviation: BMI, Body Mass Index  
*Physical Activity and dietary patterns derived from the Yale Physical Activity Survey  
*Dietary Patterns derived from the Dietary Screening Tool  
< 60 = at risk, 60-75 = at possible risk, >75 = not at risk (Bailey et al., 2009)\(^26\)
Table 2. Fisher’s Exact Test for Sarcopenia Classification Based on European Working Group on Sarcopenia in Older People (EWGSOP) Definition Comparing Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy X-ray Absortiometry (DXA)

<table>
<thead>
<tr>
<th></th>
<th>DXA Normal</th>
<th>DXA Pre-Sarcopenia</th>
<th>DXA Sarcopenia</th>
<th>DXA Weak</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMF-BIA Normal</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>SMF-BIA Pre-Sarcopenia</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>SMF-BIA Sarcopenia</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>SMF-BIA Weak</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
<td>1</td>
<td>11</td>
<td>10</td>
<td>25</td>
</tr>
</tbody>
</table>

*Normal = ALM > 5.67 kg/m², Grip Strength > 20 kg, and Gait Speed > 0.8 m/s
*Pre-Sarcopenia = ALM < 5.67 kg/m², Grip strength > 20 kg, and Gait Speed > 0.8 m/s
*Sarcopenia = ALM < 5.67 kg/m² and Grip < 20 kg or Gait Speed < 0.8 m/s
*Weak = ALM > 5.67 kg/m² and Grip < 20 kg

NOTE: Significant difference between definitions (p < 0.001)
Table 3. Fisher’s Exact Test for Sarcopenia Classification Based on the Foundation for the National Institute of Health Sarcopenia Project (FNIHSP) Definition Comparing Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy X-ray Absorptiometry (DXA)

<table>
<thead>
<tr>
<th></th>
<th>DXA Low Lean</th>
<th>DXA Normal</th>
<th>DXA Weak</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMF-BIA Low Lean</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>SMF-BIA Normal</td>
<td>3</td>
<td>7</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>SMF-BIA Weak</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Total</td>
<td>9</td>
<td>7</td>
<td>9</td>
<td>25</td>
</tr>
</tbody>
</table>

*Normal = ALM > 15.02 kg or ALM/BMI > 0.512 and Grip Strength > 16 kg
*Low Lean = ALM < 15.02 kg or ALM/BMI < 0.512 and Grip > 16 kg
*Weak = ALM > 15.02 kg or ALM/BMI > 0.512 and Grip <16 kg

NOTE: Significant difference between definitions (p < 0.001)
**FIGURES**

**Figure 1.** Study Flow Chart

Phone Screened for Initial Eligibility (n=160)

- Excluded (n=99)
  - Did not meet eligibility criteria (n=70)
  - Unavailable for time commitment (n=9)
  - Not interested (n=20)

- Pre-Screened for Eligibility (n=61)
  - Provided Informed Consent
  - Assessment of body composition, grip strength, single chair stand, and gait speed

- Excluded (n=23)
  - Did not meet sarcopenia or dynapenia guidelines

- Eligible (n=38)
  - Investigator Review for selection

Baseline Tested (n=25)
Figure 2. Pearson’s Correlation Coefficient Between Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy X-ray Absorptiometry (DXA) for the Measurement of Appendicular Lean Mass (ALM)

*A significant and strong positive correlation was observed between SMF-BIA and DXA with a correlation coefficient of 0.88 (95% CI= 0.75 to 0.95, p < 0.001).
Figure 3. Bland-Altman Plot Comparing Appendicular Lean Mass (ALM) by Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy X-ray Absorptiometry (DXA)

* A mean difference of 0.5 kg (95% CI= -1.02 to -0.02) indicates overall agreement between SMF-BIA and DXA.

* SMF-BIA overestimated ALM for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and underestimated ALM for another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared to DXA.
APPENDICES

Appendix A: Review of the Literature

Abstract

The loss of muscle mass associated with advancing age, termed sarcopenia, contributes to the development of physical disability and mobility limitation. Women are at a greater risk for developing physical disability compared to men as patterns of functional impairment related to the loss of muscle and strength (i.e. dynapenia) differ between genders. Although a universally accepted definition for sarcopenia is lacking, several working groups have established criteria based on low appendicular lean mass (ALM) and poor physical function. While dual energy x-ray absorptiometry (DXA) is considered as the gold standard method for measuring ALM, several studies have validated the use of segmental multi-frequency bioelectrical impedance (SMF-BIA) as a more portable alternative. No study to date has assessed the accuracy of SMF-BIA among older women who present with characteristics of sarcopenia and/or dynapenia.

Introduction

Sarcopenia is defined as the progressive loss of muscle mass, physical function, and strength (i.e. dynapenia) which accelerates with advancing age.\textsuperscript{1-3} The mechanisms for sarcopenia are multifactorial and include physical inactivity, malnutrition, hormonal changes, denervation of motor units, and the conversion of fast type II muscle fibers to slow type I muscle fibers, among others.\textsuperscript{2,4} As a natural
process of aging, muscle mass declines by approximately 1 to 2% per year after age 50 contributing to the loss of strength at an even greater rate.\textsuperscript{1,5,6} Muscle strength has been reported to decline 2 to 5 times faster than muscle mass with age contributing to poor physical function, mobility limitation, and disbaility.\textsuperscript{7–9} Sarcopenia is associated with several adverse health outcomes among older adults including frailty, weakness, functional decline, increased risk of falls and fractures, and loss of independence.\textsuperscript{1,2} Moreover, in the year 2000, estimated healthcare costs associated with sarcopenia were $12.6 billion for older men, and $29.5 billion for older women.\textsuperscript{10} The economic burden associated with sarcopenia is likely far higher today particularly in women, as they have a greater life expectancy and risk for functional impairment compared to men.\textsuperscript{11,12}

Although there is currently no universal definition for identifying sarcopenic individuals, several working groups have established cut-points for low lean mass in addition to markers of reduced physical functioning and muscle strength. While early definitions were based exclusively on muscle mass compared to a healthy reference population,\textsuperscript{13} the current definitions also consider performance criteria. The European Working Group on Sarcopenia in Older People (EWGSOP), the Foundation for the National Institutes of Health Sarcopenia Project (FNIHSP), and the International Working Group (IWG) are all in agreement that ALM in combination with weak grip strength and or slow gait speed be present to confirm sarcopenia status.

While a wide range of techniques are available for assessing muscle mass, DXA is considered as the gold standard in research and clinical practice to determine ALM despite its limitations including exposure to radiation, expense, and lack of
Thus, is it critical to find alternative methods for ALM assessment. The use of segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) for the measurement of muscle mass has been accepted as a valid, more portable, and less expensive alternative in several populations\textsuperscript{16–19} including older women.\textsuperscript{20,21} While some studies have validated the use of SMF-BIA for the estimation of ALM among older women,\textsuperscript{20} the device has not yet been validated for the assessment of sarcopenia based on current international definitions.

**Sarcopenia in Older Women**

Women represent the largest proportion of the elderly, and their patterns of functional impairment related to declines in muscle mass and strength differ from men.\textsuperscript{12} Women are at a greater risk for developing decreased muscle strength (dynapenia) and sarcopenia with aging which also increases their risk for mortality compared to men as they have more fat, lower absolute muscle mass, and less strength.\textsuperscript{1,22} The earlier development of muscle weakness observed in women compared to men can be partially explained by menopause as a reduction in the sex-hormone estrogen is associated with loss of bone mass and strength.\textsuperscript{11,23} Changes in the sex hormones estrogen and progesterone begin a decade or more prior to menopause, which may accelerate the morphological changes in skeletal muscle characteristic of sarcopenia. Consequently, post-menopausal women present with half the concentration of estrogen observed before menopause thus increasing their incidence of sarcopenia.\textsuperscript{24}
Women also experience earlier declines in muscle power at a rate of 3 to 4% faster than strength compared to men.\textsuperscript{24} Early declines in muscle power, defined as the ability to perform muscular work per unit of time could explain the variance in poorer physical function and subsequent disability.\textsuperscript{24,25} A longitudinal study followed 545 high-functioning women aged 75 years and older over a seven-year period to determine which baseline activities of daily living were most strongly predictive of future disability. Women with poor mobility measured by time to complete five chair stands, gait speed, and number of steps to walk 6 meters had odds ratios (95% CI) equal to 7.62 (3.86, 15.04), 6.31 (3.26, 12.19) and 5.31 (2.43, 11.59), respectively, for developing disability while women with poor grip strength had 2.81 (1.43, 5.52) times the risk of developing disability.\textsuperscript{12} Given that women experience a greater life expectancy as well as greater functional impairment associated with muscle weakness, early identification of muscle loss using accurate and clinically available techniques is especially important so that appropriate interventions can be delivered to reduce adverse health outcomes and improve quality of life.\textsuperscript{11}

**Working Definitions for Sarcopenia**

Screening individuals for clinically significant sarcopenia has presented as a major challenge for the justification of intervention strategies that could reduce disability among older adults without a universally accepted definition. As a result, several working groups have convened to establish criteria to identify individuals at risk in order to prevent adverse events associated with reduced lean mass (LM) and physical function.\textsuperscript{13,26} Muscle mass can be quantified using DXA, SMF-BIA, and
anthropometry while muscle strength can be measured most effectively by testing handgrip strength using a handheld dynamometer.\textsuperscript{27} In clinical practice, physical performance is measured using the short physical performance battery (SPPB) of tests, the get up and go test, and gait speed. The most prominent statements defining sarcopenia based on low muscle mass and physical function have come from the European Working Group on Sarcopenia in Older People (EWGSOP), International Working Group (IWG), and the Foundation for the National Institutes of Health Sarcopenia Project (FNIHSP). While early definitions were based exclusively on muscle mass compared to a healthy reference population, the current definitions also consider performance criteria.\textsuperscript{13}

The EWGSOP algorithm requires that low muscle mass accompanied by either low grip strength, slow gait speed, or a combination of all three be present for classification of pre-sarcopenia, sarcopenia, or severe sarcopenia.\textsuperscript{2,13} The EWGSOP defines low muscle mass as an ALM in kilograms relative to height squared (kg/m\textsuperscript{2}) less than 7.23 kg/m\textsuperscript{2} in men and less than 5.67 kg/m\textsuperscript{2} in women. Their cutoff values for low grip strength are set at less than 30 kg in men and less than 20 kg in women. In order to be considered slow, and individual must present with a gait speed less than 0.8 meters per second (m/s). Based on the results from screening of the above mentioned criteria, the severity of sarcopenia may be determined. Pre-Sarcopenia is defined by low muscle mass without low muscle strength whereas severe sarcopenia is defined by demonstrating all three criteria. Individuals with sarcopenia present with low muscle mass in combination with either low grip strength or slow gait speed.
The International Working Group defines sarcopenia as the age related loss of skeletal muscle mass and function caused by several factors including disuse, altered endocrine function, chronic diseases, inflammation, insulin resistance, and nutritional deficiencies which contribute to disability, hospitalization, and death. The group considers that all older patients who present with observed decrements in physical function, strength, and overall health be evaluated. Their diagnosis of sarcopenia is based on the presence of low whole body or ALM in combination with poor physical functioning. Similar to the EWGSOP criteria, the IWG confirms diagnosis of sarcopenia based on the same ALM criteria however, their cut-points are less conservative with slow gait speed defined as less than 1.0 m/s.

Rather than define sarcopenia, the FNIH have proposed a two-step clinical paradigm to identify individuals with low muscle strength and low muscle mass by first screening for mobility impairment and low muscle strength measured by gait speed and grip strength, respectively. The FNIHSP recommends that individuals be identified using either “weak with low LM” or “weak and slow with low LM” rather than use the term sarcopenia. The group is in agreement with the EWGSOP and IWG on the use of a cut-point for slow gait speed defined as less than 0.8 m/s, as it is easy to measure in most settings and is highly predictive of survival and major health outcomes. The cut-points established to identify weak individuals based on a grip strength are set as less than 26 kg in men and less than 16 kg in women compared to the EWGSOP criteria (< 30 kg in men and < 20 kg in women). Their criteria for low LM is defined as an ALM < 19.75 kg for men and < 15.02 kg for women and the criteria for low LM based on the ratio of ALM relative to body mass index (BMI) is
defined as $< 0.789$ in men and $< 0.512$ in women. The prevalence of sarcopenia in adults over 50 varies greatly depending on the definition being used therefore, adoption of an operational definition is required for effective prevention and treatment strategies to be implemented.\textsuperscript{2} A universally accepted sarcopenia definition would allow effective interventions to be delivered to at risk individuals identified using a variety of screening techniques for low ALM and low physical function.

**Evolution of Body Composition Evaluation Techniques**

Since the birth of early methods for assessing body composition, several advancements in the techniques for providing accurate regional and total body estimates of skeletal muscle mass have become widely available. Within a very short time span in the early 1970s, all three contemporary clinical and reference methods, computerized axial tomography (CT), magnetic resonance imaging (MRI), and DXA came into existence.\textsuperscript{34} Early methods (CT and MRI) have more recently developed into refined methods that have the ability to quantify regional and total body skeletal muscle mass including bioelectrical impedance analysis (BIA) and DXA, all of which have advantages and disadvantages.\textsuperscript{14}

Three dimensional imaging techniques including CT and MRI have the ability to quantify all major tissues in the human body. Computerized axial tomography consists of a rotating x-ray tube and detector, which move in a perpendicular plane to the subject. The difference in the attenuation or weakening of the x-rays as they penetrate body tissues determines the density of the underlying tissues. The attenuated
x-ray beams can then generate a computer image of the scanned area separating bone, adipose tissue, and lean tissue. An advantage of CT is its ability to construct high-quality images providing a measure of tissue composition and quality however, the degree of radiation exposure and relatively high cost limits its use in research and clinical settings.\textsuperscript{14} Unlike CT scanning, MRI does not use radiation; rather it creates images from radio frequency signals emitted by hydrogen nuclei. The fundamental MRI concept is based on interaction between nuclei of abundant hydrogen atoms and magnetic fields produced and controlled by the system’s instrumentation. Application of an external magnetic field followed by a pulsed radio frequency across a body part causes the hydrogen nuclei to line up and absorb energy. When the radio wave is turned off, the nuclei emit the energy previously absorbed thus, emitting a signal that can then be used to create an image. While CT and MRI are accepted as accurate measures of whole body composition, neither are available or affordable methods for conducting sarcopenia trials.\textsuperscript{34,35}

Although CT and MRI provide the most accurate assessment of body composition, these reference methods have several limitations including expense, equipment availability, and excessive radiation exposure with CT,\textsuperscript{36} therefore DXA has been used more frequently due to its relatively low cost and minimal radiation exposure.\textsuperscript{34,37} DXA uses an x-ray tube to evaluate bone mineral density and soft tissue composition. The attenuation of the x-rays with high and low photon energies is measurable and dependent on the thickness, density, and chemical composition of the underlying tissue.\textsuperscript{35} The scan has the ability to evaluate fat, lean soft tissue, and bone separately for the extremities, trunk, and other selected body regions. This segmental
analysis can then allow estimation of ALM for assessing skeletal muscle loss with aging. The availability of DXA, its modest scan cost, low radiation exposure, short scan time, and the extensive information provided from each scan has ultimately led to this approach being most widely used in sarcopenia research and clinical practice today.

While DXA is the most widely used method for assessing body composition, the use of BIA has grown rapidly in the past two decades as a noninvasive, portable, quick, and inexpensive alternative. Bioelectrical impedance analysis is based on the relation between the volume of a conductor and its electrical resistance, therefore skeletal muscle is a dominant conductor because it is an electrolyte rich tissue with low resistance. The devices deliver an alternating current at one or more frequencies via electrodes, and impedance to electrical flow is detected. Electrolyte-rich fluids such as body water pose the least impedance to electrical flow, while lipids and bone minerals provide the most. The traditional whole body, single frequency models have evolved into segmental multi-frequency models which can measure resistance for each body segment at a wide range of frequencies. The use of SMF-BIA has become more common as segmental analysis of the arm and leg can be empirically calibrated to DXA appendicular lean mass however, stable subject conditions are required for accurate results.

**Comparison between BIA and DXA**

Although several techniques for measuring body composition are available in research and clinical practice, DXA is considered to be the gold standard due to its
precision for distinguishing fat, bone, and muscle tissue.\textsuperscript{2,39} As an alternative to CT scans and MRI, DXA became available in 1987 as a more practical method with limited radiation exposure.\textsuperscript{34} The ability to isolate body regions during DXA analysis allowed many investigators the opportunity to evaluate fat, lean soft tissue, and bone mineral content separately for the extremities, trunk, and other selected body regions. With the introduction of portable SMF-BIA devices, the same segmental body composition analysis could be estimated with no exposure to radiation and at a very low cost.\textsuperscript{2,17,40} While earlier studies supported the validation of DXA using prediction equations for the estimation of ALM, future studies would successfully validate the use of these prediction equations by BIA.\textsuperscript{41}

While studies prior to 2003 identified good correlation between BIA and MRI using prediction equations, these equations for the estimation of ALM by BIA compared to DXA did not yet exist. Validation of a BIA equation to predict ALM compared to DXA was performed by Kyle et al.\textsuperscript{42} among 444 participants aged 22 to 94 years. Using a single frequency bioelectrical impedance device (SF-BIA), a single prediction equation taking into account predictor variables including, height$^2$/resistance, weight, gender, age, and reactance was used for each participant. The results indicated that DXA measured ALM was strongly correlated to the BIA derived resistance normalized for height, and that BIA was valid for estimating ALM with a standard error between 5\% and 7.5\% (1.1 kg and 1.5 kg). While several similar prediction equations by BIA have been published and validated against DXA for the estimation of skeletal muscle mass (SMM), general BIA prediction equations across different ages, ethnic groups, and clinical conditions had not yet been tested.\textsuperscript{10,42,43}
The aim of a study performed by Boseaus et al.\textsuperscript{44} was to validate SF-BIA prediction equations developed previously for estimating SMM among 86 male and 66 female Australian patients with clinical disorders aged 70 and over compared to DXA. Overall, the study demonstrated that SF-BIA, using a prediction equation, gave an accurate estimate of DXA derived SMM among participants with a standard error of 1.68 kg. With the introduction of validated prediction equations for the estimation of total SMM and ALM using BIA, several studies could then investigate the validity of several types of single and multi-frequency BIA models among several populations compared to DXA.

Numerous studies have investigated the validity of several bioelectrical impedance devices for the measurement of ALM compared to DXA among several populations with conflicting results. In a study by Leahy et al.\textsuperscript{16} in a healthy adult population (n= 403) aged 18 to 29 years, overall agreement between SMF-BIA (Tanita MC-180MA) and DXA for the measurement of ALM was observed. Anderson et al.\textsuperscript{17} also reported agreement between SMF-BIA (InBody720) and DXA among the 25 women aged 18 to 49 years for the estimation of ALM however, among the 25 men, an underestimation of ALM of approximately 3.0 kg was observed.\textsuperscript{17} Another similar study identified SMF-BIA (InBody230) as an appropriate alternative to DXA for the estimation of fat mass, percent body fat, and total LM but not for the evaluation of ALM among a healthy adult population between 18 and 85 years.\textsuperscript{19} While many studies report overall agreement between SMF-BIA and DXA, there appears to be consistent observation of a systematic bias with either overestimation or underestimation of ALM with some devices.
While several studies report overall agreement between several SMF-BIA devices among healthy adult populations, others aimed to validate BIA devices among older women. Of the studies that include older women, conflicting results regarding the agreement between SMF-BIA and DXA specifically for the measurement of ALM have also been observed.\textsuperscript{15,20} Buckinx et al.\textsuperscript{15} observed low agreement between SMF-BIA (InBody S10) and DXA among approximately 25 women in the subcategory of participants over the age of 65 (n= 48) using a Bland-Altman plot method. The study reported strong agreement for LM of the upper limbs and low agreement for LM in the lower limbs between the two techniques with a tendency for SMF-BIA to overestimate ALM by approximately 1.75 kg.\textsuperscript{15} The participants in the subcategory over the age of 65 years were more frequently outside the limits of agreement, therefore more participants of this age group may have been required for overall agreement to be observed. In a similar study by Kim et al.\textsuperscript{45} a larger population of community dwelling older men (n= 241) and women (n= 331) aged 65 to 87 years were included to investigate the validity of SMF-BIA (InBody 720) compared to DXA. The findings of this study compare to previous studies reporting good agreement between the two methods for the estimation of ALM, although SMF-BIA had a tendency to underestimate ALM among female participants with a bias of 1.59 kg (95% CI 1.49 to 1.68).\textsuperscript{45} A study by Kim et al.\textsuperscript{20} also reported agreement between SMF-BIA (InBody 720) and DXA among 129 frail community dwelling Japanese women aged 75 to 89 years.\textsuperscript{20} Kim et al.\textsuperscript{20} are the first to assess the validation of SMF-BIA for the measure of ALM in a heterogeneous older female participant population. In order to fill the current gap in the literature, future research efforts should investigate the accuracy of
other SMF-BIA devices among older Caucasian women for the measurement of ALM as a criterion for sarcopenia classification.

Conclusions

While some studies have reported overall agreement between SMF-BIA and DXA for the estimation of ALM among older women, others have reported conflicting results. Additional studies are required to confirm agreement between DXA and SMF-BIA under standardized testing conditions that may reduce the systematic bias reported by previous investigators. Despite the evidence in support of SMF-BIA accurately estimating ALM, no study to date has investigated the agreement between SMF-BIA and DXA among participants with characteristics of sarcopenia and/or dynapenia based on current international definitions. Future studies investigating the validation of SMF-BIA compared to DXA for accurate sarcopenia classification based on established criteria for low LM based on ALM are also required. Validation of SMF-BIA among populations of older women would provide a more portable and less expensive alternative to DXA for clinical and epidemiological screening for sarcopenia based on the measurement of ALM in addition to tests of physical function.

References:


33. McLean RR, Kiel DP. Developing Consensus Criteria for Sarcopenia: An


44. Bosaeus I, Wilcox G, Rothenberg E, Strauss BJ. Skeletal muscle mass in hospitalized elderly patients: Comparison of measurements by single-frequency

Appendix B. Phone Screen Assessment

URI Resistance Exercise Study to Reclaim Lean Muscle and Strength (URI RESTORE ME Project)

Data Sheet for Detailed Subject Telephone Interview

☐ Brief Explanation of Study

☐ Permission to Conduct Interview?    _____Yes   _____No

How did you hear about the study (if not already recorded)?_____________________________________

Name: Dr./Ms./Mrs.__________________________________________________________
Address: _______________________________________________________________________
                                                              _______________________
Phone #:________________________________________________________________________
E-Mail:  _______________________________________________________________________
Best Way and Time to Contact:_____________________________________________________

• **Time Commitment** – Available – Include 7-9am or 3-5pm MWF preference
  _____Yes   ____No     Wants to be contacted after ________ (Date)
Comment:_________________________________________________________________________

• **Proximity to URI**
  Length of commute: _____ miles or _____ minutes
  Within reasonable commute_____    Willing to make unreasonable commute_____
  Too far to commute_____

• **Age**
  Age: _____ yrs          Date of Birth: _____/_____/_____
                      MM   DD   YY
Approximate Height: ___________  Approximate Weight: ___________  BMI:
_________________

• Race
  ___ American Indian or Alaskan Native
  ___ Asian or Pacific Islander
  ___ Black, not of Hispanic origin
  ___ Hispanic
  ___ White, not of Hispanic origin
  ___ Other/Unknown

• Highest level of education completed
  ___ Less than high school
  ___ High school or GED
  ___ Some college
  ___ Two-year college degree (e.g. Associates)
  ___ Four-year college degree (e.g. B.S., B.A.)
  ___ Masters degree
  ___ Doctoral degree
  ___ Professional degree (e.g. M.D., J.D.)
  ___ Other (please specify) _______________________________________________________

• Have you attained menopause?  Yes ______  No_______
  If Yes, for how long? _____________________

• Smoking
  Always Non-Smoker ________  Non-Smoker for __________
  Smoker__________

• Physical Activity
  Participates in regular (>1x/wk for past 3 months) exercise?  Yes _____ No _____
  If yes, describe in detail (e.g. frequency, intensity, duration, mode)

________________________________________________________________________________
Describe other non-structured physical activity (e.g. leisure time, gardening, occupational, or other)

• **Cardiovascular (heart, blood, or blood vessel) conditions?**
  - No    - Yes (Record on Medical History/Treatment Form)
  Comments:________________________________________________________

• **Respiratory Conditions?**
  - No    - Yes (Record on Medical History/Treatment Form)
  Comments:________________________________________________________

• **Osteoarthritis/Degenerative Arthritis**
  - No    - Yes
  If yes, how long and what was the severity________________________________________________________

• **High Blood Pressure**
  - No
  Yes    - Controlled (Record High BP and Treatment on Medical History/Treatment Form)
  - Yes    - Uncontrolled
  Comments:________________________________________________________

• **Orthopedic conditions (knee, neck, or other back pain)**
  - No    - Yes
  If yes, describe in detail including severity
  ________________________________________________________________
• Diabetes
   ____No
   ____Yes – Type 2. If type 2, taking insulin now?
   ____________________________
   ____Yes – Type 1 (Insulin Dependent)
   Comments:_____________________________________________________
                                                                      ____________________________

• Any major surgeries as an adult?
   ____No   ____Yes
   If yes, what type (e.g. surgeries of the joints, heart surgeries, angioplasty, bypass surgery, pacemakers, etc.) and date(s)
   ____________________________
                                                                      ____________________________
                                                                      ____________________________

• Other Medical Conditions (especially those that would make exercise difficult or unsafe)
   ____No
   ____Yes (Record on Medical History/Treatment Form)
   Comments:_____________________________________________________
                                                                      ____________________________

• Medication Info – See last page
   ____No
   ____Yes (Record on Medical History/Treatment Form)
   Comments:_____________________________________________________
                                                                      ____________________________
• Personal Physician Info
  Name of Physician: __________________________________________________________
  Specialty of Physician: _______________________________________________________
  Phone Number: _______________________________________________________________
  Fax Number: _________________________________________________________________
  Address (if phone and fax unknown): __________________________________________

• Summary
  Interviewer Printed Name: ______________________________________________________

  Interviewer Signature: _________________________________________________________

  Questions/Comments: _________________________________________________________

Reviewer Initials: ______

  ______Appears to Qualify        ______Need More Information
  ______Needs Drs. Delmonico, Hatfield, Xu, or Lofgren to review
  ______Not Qualified

Questions/Comments: __________________________________________________________

________________________________________________________
Appendix C. Consent Form for Research

CONSENT FORM FOR RESEARCH

Title of Project: Effects of a Resistance Training Program in Older Women with Sarcopenia

You are invited to take part in a research project described below. The researchers will explain the project to you in detail. You should feel free to ask questions. If you have more questions later, Drs. Matthew Delmonico (Phone: 401-874-5440) and Ingrid Lofgren (401-874-5706) from the Departments of Kinesiology and Nutrition and Food Sciences at the University of Rhode Island (URI), the persons mainly responsible for this study, will discuss them with you. The general eligibility criteria for inclusion to this study include having being 1) a woman with low physical function and/or low lean mass, 2) age 65-84 years, 3) no recent medication changes, 4) post-menopausal, 5) the ability to speak and read English, 6) a body mass index of 18.5 – 45.0 kg/m² and 6) free of diseases or conditions that would prevent reasonably safe participation in an exercise program.

Description of the project:
You understand that the primary purpose of this study is to assess the role that a 12-week resistance exercise training program plays in improving muscle mass, physical functioning, and sarcopenia (the age-related loss of muscle mass) classification factors. Resistance training has been shown to be effective for improving health outcomes in older women, including physical functioning but has not been tested in women who have been identified by new guidelines as having low muscle mass and physical functioning. Another purpose of the study will be to assess the influence resistance training on changes in bone density, blood pressure, muscle function, health indicators, blood lipids (fats) and sugar, fat and protein metabolism. Your participation time will vary depending on which group to which you are randomized and can range from 3-4 hours per week. All of the testing and intervention sessions will take place on the URI Kingston campus (Independence Square building, and you are responsible for your own transportation to all of the testing and intervention sessions).

What will be done:
You understand that if you choose to participate, the study potentially requires your involvement in five phases.

PHASE 1: During Phase 1, you will undergo a screening visit to determine if you meet the criteria for sarcopenia which include low muscle mass and either 1) slow normal walking speed or 2) low grip strength. The muscle mass test simply requires you to stand barefoot on a device with metal conducting pads while holding onto another set of conducting pads with
your hands. This will tell us in less than one minute how much arm and leg muscle you have. This device uses a very low electrical current in order to estimate muscle and fat mass on your body. This test only takes about one minute to complete but is a valid and reliable measure of body composition with very few risks. The walking test simply requires you to walk four meters (about 15 feet) at your normal walking pace. The hand grip strength test only takes a couple of minutes and you will be asked to squeeze a device two times with both hands (separately) as hard as you can. Your height and weight will also be measured at this visit. If you meet the criteria that identify you as having sarcopenia, then you will be invited to take part in the project. If you do not meet these criteria, we will provide you with information about your muscle mass and physical functioning, along with information about how you can maintain or improve these health aspects on your own.

**PHASE 2.** If you are identified as having sarcopenia, then you will be invited to take part in the research trial. Preliminary testing (four visits of ~ 1–1.5 hours per visit) will be necessary. In addition to a repeat of some of the measures in Phase 1, your, waist and hip girths will be measured and you will be asked to complete some tasks to measure your ability to carry out normal daily activities at the Independence Square building. These tasks include a usual pace 400 meter (~ ¼ mile) walk, rising from a chair, standing balance tests, and short walks. Any risk of injury during the completion of these tasks will be minimized by having all sessions supervised by an exercise physiologist qualified to direct this type of testing. In addition, you will be asked to complete several health questionnaires. These include sleep quality, general health, food intake, a dietary screening tool, a balance survey, and physical activity habits.

You understand that your percent body fat and bone density will be performed using dual energy x-ray absorptiometry (DXA) located in room 129 of the Independence Square building. This will require you to lay on a table a wearing hospital scrubs for about 20 minutes for the entire procedure. A licensed radiology technician will perform the DXA scans. There is no cost to you or your insurance for these scans.

The flexibility of your leg muscles will be tested by using a simple test that requires you to attempt to touch your toes while seated. You also understand that strength assessments will be performed on machines or devices that measure how much force and how fast you can exert force through a typical range of leg, back, chest and knee extension motion. Leg strength testing will be performed by measuring the maximal amount of force that you can move through the full range of an exercise. You may experience some temporary muscle soreness as a result of the testing sessions. There is also a risk of muscle soreness or skeletal injury from strength and testing as well as from the exercise training. The investigators of this study will use procedures designed to minimize this risk.

A blood test will be done that will include two blood draws to analyze blood sugar, lipids (fats), and other blood proteins. You understand that there is a risk of bruising, pain, and in rare cases, infection or fainting as a result of blood sampling. However, these risks to you will be minimized by allowing only qualified people to draw your blood. Your blood pressure will also be assessed during this first phase.
At the end of the Phase 2 (testing), you will be randomly assigned (like a flip of a coin) to either a resistance training group or a general physical activity group for Phase 3. You understand that you are not allowed to choose which group you will be assigned.

**PHASE 3: INTERVENTION**

**Resistance Training Sessions (Resistance Training Group)**

If you are randomized to the resistance training exercise group, you will also be asked to participate in three (3) supervised exercise sessions per week (~45 minutes per visit) for the 12-week intervention in the Independence Square building, room 190. During each resistance training session, you will be asked to exercise on machines or free weights that offer resistance against extending and flexing your arms, legs, and trunk region. All sessions will start with a resting blood pressure and a brief warm-up. The first several resistance training sessions will begin with lighter resistances to get you used to the resistance training program. The resistances will be gradually increased based on individual progress. The resistance will always be adjusted so that you are exercising at near maximal effort. You will be able to provide feedback using standardized pain and discomfort rating scales. Your overall progress will be monitored by an exercise specialist so that you are able to tolerate the exercise. Each session will end with a cool-down and a final blood pressure measurement. No special clothing is required, but you should dress in clothing that is comfortable and that allows you to move freely. You will also be instructed to stop exercising immediately if you experience chest pain, muscle injuries, or any other unexpected symptoms. Although you will always have supervision when doing exercise during this study, if you ever experience chest pain while exercising at other times, you should immediately call 911 to seek emergency care and notify your primary care physician. If you have any problems or injuries, you should also notify a member of the study team. Study team members and their phone numbers are noted on the first page of this consent form.

**General Physical Activity Sessions (Active Control Group)**

If you are assigned to the active control group, you will also be asked to participate in three (3) supervised exercise sessions per week (~45 minutes per visit) for the 12-week intervention in the Independence Square building, room 190. During each general physical activity session, you will engage in individual and group exercise sessions to increase your overall weekly physical activity. Activity sessions will vary but will include activities recommended by the American College of Sports Medicine for adults 65 years and older. Some of these activities may include walking, Tai Chi, light calisthenics, and stretching. All sessions will start with a resting blood pressure and a brief warm-up. The first several exercise sessions will begin with very light activities to get you used to the training program. The difficulty of the exercises will be gradually increased based on individual progress. You will be able to provide feedback using standardized pain and discomfort rating scales. Your overall progress will be monitored by an exercise specialist so that you are able to tolerate the exercise. Each session will end with a cool-down and a final blood pressure measurement. No special clothing is required, but you should dress in clothing that is comfortable and that allows you to move freely. You will also be instructed to stop exercising immediately if you experience chest pain, muscle injuries, or any other unexpected symptoms. Although you will always have supervision when doing
exercise training during this study, if you ever experience chest pain while exercising at other times, you should immediately call 911 to seek emergency care and notify your primary care physician. If you have any problems or injuries, you should also notify a member of the study team. Study team members and their phone numbers are noted on the first page of this consent form.

**PHASE 4:** Phase 4 will be a repeat of previously taken measures at the mid-point (week 6) and at the end (after week 12) of the 12-week exercise intervention.

**PHASE 5:** Phase 5 (the final phase) of the project will be six month follow-up testing session after Phase 4. You do not need to do any special activity or diet during this period.

**Risks or discomfort:**
You understand that it is possible that heart or blood vessel problems could arise during your participation in the testing or training involved in this study. Although highly unusual, it is possible that these problems could lead to a heart attack, stroke or even death. Therefore, prior evaluation and written clearance with a signature from your personal physician is strongly encouraged for you to participate in this study. You also understand that it is possible that these risks will not be eliminated completely, even with a medical evaluation prior to participation in the study. However, the investigators believe the risk of harm from study participation is relatively small and that the benefits of the study will likely outweigh any potential risks. Additionally, you understand that with the testing described above, resistance training and exercise in general there is a risk of muscle soreness or other muscle injury as well as skeletal injury. Because exercise in this study does require some degree of balance, there is also a risk of falling associated with exercise. However, the investigators will take precautions in order to reduce the likelihood that these adverse events will occur.

You understand that there will also be a very low total radiation dose for the DXA scans (~39 millirem), which is about one-fifth the radiation dose of a standard chest X-ray and is well below the maximal annual radiation dose (5 rem) allowed for exposure in the workplace. Naturally occurring radiation (cosmic radiation, radon gas, etc.) gives each person a whole body radiation dose of about 300 millirems per year. Therefore, the total dose of radiation exposure due to DXA is considered low. The major risk from high radiation exposure is passing on damaged genes (genetic mutations) to offspring. Therefore, this risk is of primarily a concern for those who are of child-bearing age.

**In case there is any injury to the subject:**
In the event of physical injury resulting from participation in this study, upon your consent, emergency treatment will be available at South Country Hospital with the understanding that any injury that required medical attention becomes your financial responsibility. You understand that URI will not provide any medical or hospitalization insurance coverage for participants in this research study, nor will they provide compensation for any injury sustained as a result of this research study, except as required by law.

You understand that if you are injured while participating in this research project as a result of negligence of all state employees who are involved in this research project, you may be able to be compensated for your injuries in accordance with the requirements of the Federal

Initial | Date | Page 4 of 6
Tort Claims Act. If you are a federal employee acting within the scope of your employment, you may be entitled to benefits in accordance with the Federal Employees Compensation Act.

Confidentiality:
All information collected in this study is confidential, and your name will not be identified and linked to any electronic study data at any time to anyone other than the principal investigators of the study. Your data will be coded with an ID number only, which will be linked back to you only by the principal investigators of the study. Your part in this study is confidential within legal limits. The researchers and the University of Rhode Island will protect your privacy, unless they are required by law to report information to city, state or federal authorities, or to give information to a court of law. Otherwise, none of the information will identify you by name. All study data, including this consent form, will be locked in a file cabinet and also stored in a study computer with a password secured in our study office (Independence Square building, Suite P, room 119).

Benefits of this study:
You understand that this study is not designed to help you personally, but may help the investigators better understand which interventions are the most effective in helping women who have sarcopenia improve their muscle mass and physical function. However, because of what is already known regarding the effects of resistance training and exercise in general, it is likely that you will notice some benefits. These potential benefits include improved strength, mobility and blood pressure.

For your participation in the study and after the study is completed, you will receive, free of charge, information about your blood pressure, blood test results, body composition, muscle strength, and physical function.

Decision to quit at any time:
You understand that is your decision and your decision alone whether or not you consent to participate in this study. You are free to ask questions about this study before you decide whether or not to consent to participate in it. Also, if you consent to participate in the study you are free to withdraw from participation at any time without penalty or coercion, or without any requirement that you provide an explanation to anyone of your decision to withdraw. You or your insurance company will not be charged for the classes or training sessions.

Rights and Complaints:
If you are not satisfied with the way this study is performed, you may discuss your complaints with the principal investigators, Drs. Matthew Delmonico at (401) 874-5440, Disa Hartfield at (401) 874-5183, Ingrrid Loefgren at (401) 874-5869, or Furong Yu (401) 874-2412 (anonymously, if you choose). In addition, if this study causes you any injury or if you have questions about your rights as a research subject you may contact the office of the Vice President for the Division of Research and Economic Development, Carlotti Administration Building, 2nd Floor, 75 Lower College Road, Suite 2, University of Rhode Island, Kingston, Rhode Island; telephone: (401) 874-4576.

Alternatives to study participation: If you choose not to participate in this study, you are encouraged to discuss with your physician about exercise strategies.
You have read and understand the above information in the Consent Form and have been given adequate opportunity to ask the investigators any questions you have about the study. Your questions, if any, have been answered by the investigators to your satisfaction. Your signature on this form means that you understand the information and you agree to voluntarily participate in this study.

Signature of Participant

Signature of Researcher

Typed/printed Name

Typed/printed name

Date

Date

By signing again below you give permission for the investigators to store and use your blood samples for future research only related to the study objectives.

Signature of Participant

Signature of Researcher

Typed/printed Name

Typed/printed name

Date

Date

Please sign both consent forms, keeping one for you.
Appendix D. Medical History

PHYSICAL FITNESS Activity 2.2

Medical/Health Questionnaire

According to the American College of Sports Medicine, a medical examination and clinical exercise test is recommended prior to (1) moderate or vigorous exercise training for those at high risk for disease, and (2) vigorous exercise training for moderate-risk individuals. The ACSM recommends that the pretest medical history be thorough and include 11 components: medical diagnoses, previous physical examination findings, history of symptoms, recent illness, hospitalization or surgical procedures, orthopedic problems, medication use and drug allergies, lifestyle habits, exercise history, work history, and family history of disease. The following medical and health questionnaire meets these criteria and can be used to gain a useful history on clients at fitness-testing facilities located in worksites, hospitals, and universities. In this activity, select a faculty member or member of the community that you feel would benefit from this process. Have the person answer the questions in the medical questionnaire, and then summarize important findings in the following blanks.

1. Symptoms or signs of disease:

2. Chronic disease risk factors:

3. Personal and family medical history:

4. Medications:

5. Summary of lifestyle habits:
Medical/Health Questionnaire

Personal Information

Today’s date __________________ Please print your name __________________

How old are you? ______ years  Sex ☐ Male; ☐ Female

Please circle the highest grade in school you have completed:

Elementary school  1  2  3  4  5  6  7  8
High school  9  10  11  12
College/Postgrad  13  14  15  16  17  18  19  20+

What is your marital status? ☐ Single; ☐ Married; ☐ Widowed; ☐ Divorced/Separated

Race or ethnic background:

☐ White, not of Hispanic origin  ☐ American Indian/Alaskan native  ☐ Asian
☐ Black, not of Hispanic origin  ☐ Pacific Islander  ☐ Hispanic

What is your job or occupation? Check the one that applies to the greatest percentage of your time.

☐ Health professional  ☐ Disabled, unable to work  ☐ Service
☐ Manager, educator, professional  ☐ Operator, fabricator, laborer  ☐ Unemployed
☐ Skilled crafts  ☐ Homemaker  ☐ Student
☐ Technical, sales, support  ☐ Retired  ☐ Other

Symptoms or Signs Suggestive of Disease

Place a check in the box if your answer is “yes.”

☐ 1. Have you experienced unusual pain or discomfort in your chest, neck, jaw, arms, or other areas that may be due to heart problems?

☐ 2. Have you experienced unusual fatigue or shortness of breath at rest, during usual activities, or during mild-to-moderate exercise (e.g., climbing stairs, carrying groceries, brisk walking, cycling)?

☐ 3. Have you had any problems with dizziness or fainting?

☐ 4. When you stand up, or sometimes during the night while you are sleeping, do you have difficulty breathing?

☐ 5. Do you suffer from swelling of the ankles (ankle edema)?

☐ 6. Have you experienced an unusual and rapid throbbing or fluttering of the heart?

☐ 7. Have you experienced severe pain in your leg muscles during walking?

☐ 8. Has a doctor told you that you have a heart murmur?

☐ 9. Are you a male over age 45 years, or a female over age 55 years, or a female who has experienced premature menopause and is not on estrogen replacement therapy?

☐ 10. Has your father or brother had a heart attack or died suddenly of heart disease before age 55 years; has your mother or sister experienced these heart problems before age 65 years?

☐ 11. Are you a current cigarette smoker?

☐ 12. Has a doctor told you that you have high blood pressure (more than 140/90 mm Hg), or are you on medication to control your blood pressure?

☐ 13. Is your total serum cholesterol greater than 240 mg/dl, or has a doctor told you that your cholesterol is at a high-risk level?

☐ 14. Do you have diabetes mellitus?

☐ 15. Are you physically inactive and sedentary (little physical activity on the job or during leisure time)?

☐ 16. During the past year, would you say that you experienced enough stress, strain, and pressure to have a significant effect on your health?

☐ 17. Do you eat foods nearly every day that are high in fat and cholesterol such as fatty meats, cheese, fried foods, butter, whole milk, or eggs?

☐ 18. Do you tend to avoid foods that are high in fiber such as whole-grain breads and cereals, fresh fruits, or vegetables?

☐ 19. Do you weigh 30 or more pounds more than you should?

☐ 20. Do you average more than two alcoholic drinks each day?
21. Please check which of the following conditions you have had or now have. Also check medical conditions in your family (father, mother, brother[s], or sister[s]). Check as many as apply.

<table>
<thead>
<tr>
<th>Personal</th>
<th>Family</th>
<th>Medical Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Coronary heart disease, heart attack, coronary artery surgery</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Angina</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>High blood pressure</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Peripheral vascular disease</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Phlebitis or emboli</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Other heart problems (specify: ______________________)</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Lung cancer</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Prostate cancer</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Colorectal cancer (bowel cancer)</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Skin cancer</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Other cancer (specify: ______________________)</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Stroke</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Chronic obstructive pulmonary disease (emphysema)</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Asthma</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Bronchitis</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Thyroid problems</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Kidney disease</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Liver disease (cirrhosis of the liver)</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Hepatitis</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Gallstones/gallbladder disease</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Osteoporosis</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Arthritis</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Gout</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Anemia (low iron)</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Bone fracture</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Major injury to foot, leg, knee, hip, or shoulder</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Major injury to back or neck</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Stomach/duodenal ulcer</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Rectal growth or bleeding</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Cataracts</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Glaucoma</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Hearing loss</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Depression</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>High anxiety, phobias</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Substance abuse problems (alcohol, other drugs, etc.)</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Eating disorders (anorexia, bulimia)</td>
</tr>
<tr>
<td>❑</td>
<td>❑</td>
<td>Problems with menstruation</td>
</tr>
</tbody>
</table>
22. Please check any of the following medications you currently take regularly. Also give the name of the medication.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Name of Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart medicine</td>
<td></td>
</tr>
<tr>
<td>Blood pressure medicine</td>
<td></td>
</tr>
<tr>
<td>Blood cholesterol medicine</td>
<td></td>
</tr>
<tr>
<td>Hormones</td>
<td></td>
</tr>
<tr>
<td>Birth control pills</td>
<td></td>
</tr>
<tr>
<td>Medicine for breathing/lungs</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td></td>
</tr>
<tr>
<td>Other medicine for diabetes</td>
<td></td>
</tr>
<tr>
<td>Arthritis medicine</td>
<td></td>
</tr>
<tr>
<td>Medicine for depression</td>
<td></td>
</tr>
<tr>
<td>Medicine for anxiety</td>
<td></td>
</tr>
<tr>
<td>Thyroid medicine</td>
<td></td>
</tr>
<tr>
<td>Medicine for ulcers</td>
<td></td>
</tr>
<tr>
<td>Painkiller medicine</td>
<td></td>
</tr>
<tr>
<td>Allergy medicine</td>
<td></td>
</tr>
<tr>
<td>Other (please specify)</td>
<td></td>
</tr>
</tbody>
</table>

23. In general, compared to other persons your age, rate how physically fit you are:

- Not at all physically fit
- Somewhat physically fit
- Extremely physically fit

24. Outside of your normal work or daily responsibilities, how often do you engage in exercise that at least moderately increases your breathing and heart rate and makes you sweat, for at least 20 minutes (such as brisk walking, cycling, swimming, jogging, aerobic dance, stair climbing, rowing, basketball, racquetball, vigorous yard work)?

- 5 or more times per week
- 3-4 times per week
- 1-2 times per week
- Less than 1 time per week
- Seldom or never

25. How much hard physical work is required on your job?

- A great deal
- A moderate amount
- A little
- None

26. How long have you exercised or played sports regularly?

- I do not exercise regularly
- Less than 1 year
- 1-2 years
- 2-5 years
- 5-10 years
- More than 10 years
Diet

27. On average, how many servings of fruit do you eat per day? (One serving = 1 medium apple, banana, orange, etc.; ½ cup of chopped, cooked, or canned fruit; ½ cup of fruit juice.)
   - None
   - 1
   - 2
   - 3
   - 4 or more

28. On average, how many servings of vegetables do you eat per day? (One serving = ½ cup cooked or chopped raw, 1 cup raw leafy, ½ cup of vegetable juice.)
   - None
   - 1–2
   - 3
   - 4
   - 5 or more

29. On average, how many servings of bread, cereal, rice, or pasta do you eat per day? (One serving = 3 slice of bread; 1 ounce of ready-to-eat cereal, ¼ cup of cooked cereal, rice, or pasta.)
   - None
   - 1–3
   - 4–6
   - 7–9
   - 10 or more

30. When you use grain and cereal products, do you emphasize:
   - Whole grain, high fiber
   - Mixture of whole grain and refined
   - Refined, low fiber

31. On average, how many servings of red meat (not lean) do you eat per day? (One serving = 2–3 ounces of steak, roast beef, lamb, pork chops, ham, burgers, etc.)
   - None
   - 1
   - 2
   - 3
   - 4 or more

32. On average, how many servings of fish, poultry, lean meat, cooked dry beans, peanut butter, or nuts do you eat per day? (One serving = 2–3 ounces of meat, ½ cup of cooked dry beans, 2 tablespoons of peanut butter, or ¼ cup of nuts.)
   - None
   - 1
   - 2
   - 3
   - 4 or more

33. On average, how many servings of dairy products do you eat per day? (One serving = 1 cup of milk or yogurt, 1.5 ounces of natural cheese, 2 ounces of processed cheese.)
   - None
   - 1
   - 2
   - 3
   - 4 or more

34. When you use dairy products, do you emphasize
   - Regular
   - Low fat
   - Nonfat

35. How would you characterize your intake of fats and oils (e.g., regular salad dressings, butter or margarine, mayonnaise, vegetable oils)?
   - High
   - Moderate
   - Low

Body Weight

36. How tall are you (without shoes)? _____ feet _____ inches

37. How much do you weigh (minimal clothing and without shoes)? _____ pounds

38. What is the most you have ever weighed? _____ pounds

39. Are you now trying to
   - Lose weight
   - Gain weight
   - Stay about the same
   - Not trying to do anything

Psychological Health

40. How have you been feeling in general during the past month?
   - In excellent spirits
   - In very good spirits
   - In good spirits mostly
   - I’ve been up and down in spirits a lot
   - In low spirits mostly
   - In very low spirits

41. During the past month, would you say that you experienced _____ stress?
   - A lot of
   - Moderate
   - Relatively little
   - Almost none

42. In the past year, how much effect has stress had on your health?
   - A lot
   - Some
   - Hardly any or none

43. On average, how many hours of sleep do you get in a 24-hour period?
   - Less than 5
   - 5–6.9
   - 7–9
   - More than 9
Substance Use

44. Have you smoked at least 100 cigarettes in your entire life?  
   ☐ Yes       ☐ No

45. How would you describe your cigarette smoking habits?  
   ☐ Never smoked  
   ☐ Used to smoke  
   ☐ Still smoke  
   How many years has it been since you smoked? ______ years
   How many cigarettes a day do you smoke on average? ______ cigarettes/day

46. How many alcoholic drinks do you consume? (A “drink” is a glass of wine, a wine cooler, a bottle/can of beer, a shot of liquor, or a mixed drink.)  
   ☐ Never use alcohol  
   ☐ Less than 1 per week  
   ☐ 1-6 per week  
   ☐ 1 per day  
   ☐ 2-3 per day  
   ☐ More than 3 per day

Occupational Health

47. Please describe your main job duties.

<table>
<thead>
<tr>
<th></th>
<th>All of the time</th>
<th>Most of the time</th>
<th>Some of the time</th>
<th>Rarely or never</th>
</tr>
</thead>
<tbody>
<tr>
<td>48. After a day's work, do you often have pain or stiffness that lasts for more than 3 hours?</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>49. How often does your work entail repetitive pushing and pulling movements or lifting while bending or twisting, leading to back pain?</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
Appendix E. Baseline Data Collection Sheet

**URI RESTORE ME Study Data Sheet**

Baseline Testing Day 1  
Participant ID #:  Date:

<table>
<thead>
<tr>
<th>Measurements</th>
<th>Baseline Testing Day 1</th>
<th>Initial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting Heart Rate 1 (bpm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting Heart Rate 2 (bpm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting Blood Pressure 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting Blood Pressure 2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Grip Strength (kilograms)

Dynamometer Setting:  Best Grip Trial:

<table>
<thead>
<tr>
<th>Grip R1:</th>
<th>Grip R2:</th>
<th>Grip L1:</th>
<th>Grip L2:</th>
</tr>
</thead>
</table>

Baseline Testing Day 1
Participant ID#: Date:

SPPB

BALANCE SCORING:

☐ A. Side-by-side-stand
  ☐ Held for 10 sec □ 1 point
  ☐ Not held for 10 sec □ 0 points
  ☐ Number of seconds held if less than 10 sec:____sec
  ☐ Not attempted □ 0 points
  ☐ If participant did not attempt test or failed, check why:
    ☐ Participant could not walk unassisted □
    ☐ Not attempted, you felt unsafe □
    ☐ Not attempted, participant felt unsafe □
    ☐ Participant unable to understand instructions □
    ☐ Other (Specify) □
    ☐ Participant refused □
  ☐ If 0 points, end Balance Tests

☐ B. Semi-Tandem Stand
  ☐ Held for 10 sec □ 1 point
  ☐ Not held for 10 sec □ 0 points
  ☐ Number of seconds held if less than 10 sec:____sec
  ☐ Not attempted □ 0 points
  ☐ If participant did not attempt test or failed, check why:
    ☐ Participant could not walk unassisted □
    ☐ Not attempted, you felt unsafe □
    ☐ Not attempted, participant felt unsafe □
    ☐ Participant unable to understand instructions □
    ☐ Other (Specify) □
    ☐ Participant refused □
  ☐ If 0 points, end Balance Tests

☐ C. Tandem Stand
  ☐ Held for 10 sec □ 2 points
  ☐ Held for 3 to 9.99 sec □ 1 point
  ☐ Held for < than 3 sec □ 0 points
  ☐ Not attempted □ 0 points
  ☐ If participant did not attempt test or failed, check why:
    ☐ Participant could not walk unassisted □
    ☐ Not attempted, you felt unsafe □
    ☐ Not attempted, participant felt unsafe □
    ☐ Participant unable to understand instructions □
    ☐ Other (Specify) □
    ☐ Participant refused □

☐ D. Total Balance Tests score ______(sum points)

☐ For 4-Meter Walk:
  ☐ If time is more than 8.70 sec: □ 1 point
If time is 6.21 to 8.70 sec: 2 points
If time is 4.82 to 6.20 sec: 3 points
If time is less than 4.82 sec: 4 points

CHAIR SCORING:

☐ Single Chair Stand Test:
   o Safe to stand without help YES □ NO □
   o Participant stood without using arms YES □ NO □ If yes go to repeated stand
   o Participant used arms to stand YES □ NO □ If yes end test; score as 0 points
   o Test not completed □ End test; score as 0 points
   o If participant did not attempt test or failed, check why:
     o Tried but unable □
     o Participant could not walk unassisted □
     o Not attempted, you felt unsafe □
     o Not attempted, participant felt unsafe □
     o Participant unable to understand instructions □
     o Other (Specify) □
     o Participant refused □

☐ Repeated Chair Stand Test
   o Safe to stand five times Yes □ No □ If five stands completed record time
   o Time to complete five stands _____ sec
   o If participant did not attempt test or failed, circle why:
     o Tried but unable □
     o Participant could not walk unassisted □
     o Not attempted, you felt unsafe □
     o Not attempted, participant felt unsafe □
     o Participant unable to understand instructions □
     o Other (Specify) □
     o Participant refused □

☐ Scoring the Repeated Chair Test
   o Participant unable to complete 5 chair stands or completes stands in >60 sec: □
     0 points
   o If chair stand time is 16.70 sec or more: □ 1 points
   o If chair stand time is 13.70 to 16.69 sec: □ 2 points
   o If chair stand time is 11.20 to 13.69 sec: □ 3 points
   o If chair stand time is 11.19 sec or less: □ 4 points

☐ Scoring for Complete Short Physical Performance Battery
   ☐ Total Balance Test score _____ points
   ☐ Gait Speed Test score _____ points
   ☐ Chair Stand Test score _____ points
   ☐ Total Score _____ points (sum of points above)
<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
<th>Date Completed</th>
<th>Initial</th>
</tr>
</thead>
<tbody>
<tr>
<td>400m walk (sec)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPPB</td>
<td>points scored</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single Leg Stand, 10 sec</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sit and Reach (+/- cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timed Up and Go 1 (sec)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timed Up and Go 2 (sec)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Baseline Testing
Participant ID #: Date:

<table>
<thead>
<tr>
<th>Measurements</th>
<th>Date</th>
<th>Initial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting Heart Rate 1 (bpm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting Heart Rate 2 (bpm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting Blood Pressure 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting Blood Pressure 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Draw 1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anthropometrics</th>
<th>Measurement 1</th>
<th>Measurement 2</th>
<th>Average</th>
<th>Initial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height (inches)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (lbs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist Circumference (inches)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Circumference (inches)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist to Hip Ratio</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
Baseline Testing  
Participant ID#:  
Date:

<table>
<thead>
<tr>
<th>Measurements</th>
<th>Baseline Testing Day 1</th>
<th>Initial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting Heart Rate 1 (bpm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting Heart Rate 2 (bpm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting Blood Pressure 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting Blood Pressure 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Draw 2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Results collected</th>
<th>Date</th>
<th>Initial</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEXA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**In-Body: BIA**  
Date:

<table>
<thead>
<tr>
<th>Voided Bladder</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Height:</th>
<th>Weight:</th>
<th>BMI:</th>
</tr>
</thead>
<tbody>
<tr>
<td>R Arm LM:</td>
<td>L Arm LM:</td>
<td>R Leg LM:</td>
</tr>
</tbody>
</table>

| Total ALM: |
Appendix F. Yale Physical Activity Survey

YALE PHYSICAL ACTIVITY SCALE

Interviewer: I will ask you about some common types of physical activities. Please tell me if you did them during a typical week in the last month. Our interest is learning about the types of physical activities that are a part of your regular work and leisure routines. For each activity you did, please tell me how many hours you spent doing the activity during a typical week.

Work: (Number of hours per week)
1. _____ Shopping (e.g., grocery, clothes)
2. _____ Stair climbing while carrying a load
3. _____ Laundry (time loading, unloading, hanging, folding only)
4. _____ Light housework: tidying, dusting, sweeping; collecting trash in home; polishing; indoor gardening; ironing
5. _____ Heavy housework: vacuuming, mopping; scrubbing floors and walls; moving furniture, boxes, or garbage cans
6. _____ Food preparation (10+ minutes in duration): chopping, stirring, moving about to get food items, pans
7. _____ Food service (10+ minutes in duration): setting table; carrying food; serving food
8. _____ Dish washing (10+ minutes in duration): clearing table; washing/drying dishes, putting dishes away
9. _____ Light home repair: small appliance repair; light home maintenance/repair
10. _____ Heavy home repair: painting, carpentry, washing/polishing car
11. _____ Other: _______________________

Yard work: (Number of hours per week)
12. _____ Gardening: planting, weeding, digging, hoeing
13. _____ Lawn mowing (walking only)
14. _____ Clearing walks/driveway: sweeping, shoveling, raking
15. _____ Other: _______________________


Caretaking: (Number of hours per week)
16. _____ Older or disabled person (lifting, pushing wheelchair)
17. _____ Childcare (lifting, carrying, pushing stroller)

Exercise: (Number of hours per week)
18. _____ Brisk walking (10+ minutes in duration)
19. _____ Pool exercise, stretching, yoga
20. _____ Vigorous calisthenics, aerobics
21. _____ Cycling, exercycle
22. _____ Swimming (laps only)
23. _____ Other: ______________________

Recreational Activities: (Number of hours per week)
24. _____ Leisurely walking (10+ minutes in duration)
25. _____ Needlework: knitting, sewing, needlepoint, etc.
26. _____ Dancing (mod/fast): line, ballroom, tap, square, etc.
27. _____ Bowling, boccie
28. _____ Golf (walking to each hole only)
29. _____ Racquet sports: tennis, racquetball
30. _____ Billiards
31. _____ Other: ______________________
YALE PART 2

Now I would like to ask about certain types of activities that you have done during the past month. I will ask you about how much vigorous activity, leisurely walking, sitting, standing, and other things that you usually do.

32. About how many times during the month did you participate in vigorous activities that lasted at least 10 minutes and caused large increases in breathing, heart rate, or leg fatigue or caused you to sweat?

<table>
<thead>
<tr>
<th>Not at all (go to Q34)</th>
<th>1-3 Times Per Month</th>
<th>1-2 Times Per Week</th>
<th>3-4 Times Per Week</th>
<th>5 or more Times Per Week</th>
</tr>
</thead>
</table>

33. About how long do you do this vigorous activity each time?

<table>
<thead>
<tr>
<th>Not applicable</th>
<th>10-30 minutes</th>
<th>31-60 minutes</th>
<th>60 or more minutes</th>
</tr>
</thead>
</table>

34. Think about the walks you have taken during the past month. About how many times per month did you walk for at least 10 minutes or more without stopping which was not strenuous enough to cause large increases in breathing, heart rate, or leg fatigue or cause you to sweat?

<table>
<thead>
<tr>
<th>Not at all (go to Q36)</th>
<th>1-3 Times Per Month</th>
<th>1-2 Times Per Week</th>
<th>3-4 Times Per Week</th>
<th>5 or more Times Per Week</th>
</tr>
</thead>
</table>

35. When you did this walking, for how many minutes did you do it?

<table>
<thead>
<tr>
<th>Not applicable</th>
<th>10-30 minutes</th>
<th>31-60 minutes</th>
<th>60 or more minutes</th>
</tr>
</thead>
</table>

36. About how many hours a day do you spend moving around on your feet while doing things? Please report only the time that you are actually moving.

<table>
<thead>
<tr>
<th>Not at all</th>
<th>Less than 1 hr per day</th>
<th>1 to less than 3 hrs per day</th>
<th>3 to less than 5 hrs per day</th>
<th>5 to less than 7 hrs per day</th>
<th>7 + hrs per day</th>
</tr>
</thead>
</table>

37. Think about how much time you spend standing or moving around on your feet on an average day during the past month. About how many hours per day do you stand?

<table>
<thead>
<tr>
<th>Not at all</th>
<th>Less than 1 hr per day</th>
<th>1 to less than 3 hrs per day</th>
<th>3 to less than 5 hrs per day</th>
<th>5 to less than 7 hrs per day</th>
<th>7 + hrs per day</th>
</tr>
</thead>
</table>
38. About how many hours did you spend sitting on an average day during the past month?

<table>
<thead>
<tr>
<th>Not at all</th>
<th>Less than 3 hrs</th>
<th>3 hrs to less than 6 hrs</th>
<th>6 hrs to less than 8 hrs</th>
<th>8 + hrs</th>
</tr>
</thead>
</table>

39. About how many flights of stairs do you climb up each day?  
(Let 10 steps = 1 flight)

40. Please compare the amount of physical activity that you do during other seasons of the year with the amount of activity you just reported for a typical week in the past month. For example, in the summer, do you do more or less activity than what you reported doing in the past month?  
(Interviewer – mark the right category for each season)

<table>
<thead>
<tr>
<th></th>
<th>Lot more</th>
<th>Little more</th>
<th>Same</th>
<th>Little less</th>
<th>Lot less</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spring</td>
<td>1.3</td>
<td>1.15</td>
<td>0</td>
<td>.65</td>
<td>.7</td>
</tr>
<tr>
<td>Summer</td>
<td>1.3</td>
<td>1.15</td>
<td>0</td>
<td>.65</td>
<td>.7</td>
</tr>
<tr>
<td>Fall</td>
<td>1.3</td>
<td>1.15</td>
<td>0</td>
<td>.65</td>
<td>.7</td>
</tr>
<tr>
<td>Winter</td>
<td>1.3</td>
<td>1.15</td>
<td>0</td>
<td>.65</td>
<td>.7</td>
</tr>
</tbody>
</table>
Appendix G. Dietary Screening Tool

DIRECTIONS: Please check one response to each question that best describes how you eat.

How often do you usually eat fruit as a snack?
___ Never
___ Less than once a week
___ 1 or 2 times a week
___ 3 or more times a week

How often do you usually eat whole grain breads?
___ Never or less than once a week
___ 1 or 2 times a week
___ 3 or more times a week

How often do you usually eat whole grain cereals?
___ Never or less than once a week
___ 1 or 2 times a week
___ 3 or more times a week

How often do you usually eat candy or chocolate?
___ Never
___ Less than once a week
___ 1 or 2 times a week
___ 3 or more times a week

How often do you eat crackers, pretzels, chips, or popcorn?
___ Never
___ Less than once a week
___ 1 or 2 times a week
___ 3 or more times a week

How often do you eat cakes or pies?
___ Never
___ Less than once a week
___ 1 or 2 times a week
___ 3 or more times a week
How often do you eat cookies?
   ____ Never
   ____ Less than once a week
   ____ 1 or 2 times a week
   ____ 3 or more times a week

How often do you eat ice cream?
   ____ Never
   ____ Less than once a week
   ____ 1 or 2 times a week
   ____ 3 or more times a week

How often do you eat cold cuts, hot dogs, lunchmeats or deli meats?
   ____ Never or less than once a week
   ____ 1 or 2 times a week
   ____ 3 or more times a week

How often do you eat bacon or sausage?
   ____ Never or less than once a week
   ____ 1 or 2 times a week
   ____ 3 or more times a week

How often do you eat carrots, sweet potatoes, broccoli, or spinach?
   ____ Never
   ____ Less than once a week
   ____ 1 or 2 times a week
   ____ 3 or more times a week

How often do you eat fruit (not including juice)? Please include fresh, canned or frozen fruit.
   ____ Never or Less than once a week
   ____ 1 or 2 times a week
   ____ 3 to 5 times a week
   ____ Every day or almost every day

How often do you eat hot or cold breakfast cereal?
   ____ Never
   ____ Less than once a week
   ____ 1 or 2 times a week
   ____ 3 to 5 times a week
   ____ Every day or almost every day
How often do you drink some kind of juice at breakfast?
____ Never or Less than once a week
____ 1 or 2 times a week
____ 3 to 5 times a week
____ Every day or almost every day

How often do you eat chicken or turkey?
____ Never or less than once a week
____ 1 or 2 times a week
____ More than 3 times a week

How often do you drink a glass of milk?
____ Never or Less than once a week
____ 1 or 2 times a week
____ 3 to 5 times a week
____ Every day or almost every day
____ More than once every day

Do you usually add butter or margarine to foods like bread, rolls, or biscuits?
____ Yes
____ No

Do you usually add fat (butter, margarine or oil) to potatoes and other vegetables?
____ Yes
____ No

Do you use gravy (when available) at meals?
____ Yes
____ No

Do you usually add sugar or honey to sweeten your coffee or tea?
____ Yes
____ No

Do you usually drink wine, beer or other alcoholic beverages?
____ Yes
____ No
How often do you eat fish or seafood that IS NOT fried?

_____ Never
_____ Less than once a week
_____ Once a week
_____ More than once a week

How many servings of milk, cheese, or yogurt do you usually have each DAY?

_____ None
_____ One
_____ Two or more

How many different vegetable servings do you usually have at your main meal of the day?

_____ None
_____ One
_____ Two
_____ Three or more

Which of the following best describes your nutritional supplement use?

_____ I don’t use supplements
_____ I use supplements other than vitamins and mineral
_____ I use a multivitamin/mineral preparation (e.g. Centrum)